These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 27771485)

  • 21. Rational excipient selection for co-amorphous formulations.
    Korhonen O; Pajula K; Laitinen R
    Expert Opin Drug Deliv; 2017 Apr; 14(4):551-569. PubMed ID: 27267873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular implications of drug-polymer solubility in understanding the destabilization of solid dispersions by milling.
    Yang Z; Nollenberger K; Albers J; Qi S
    Mol Pharm; 2014 Jul; 11(7):2453-65. PubMed ID: 24897345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters.
    Marsac PJ; Li T; Taylor LS
    Pharm Res; 2009 Jan; 26(1):139-51. PubMed ID: 18779927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An investigation into the role of polymeric carriers on crystal growth within amorphous solid dispersion systems.
    Tian Y; Jones DS; Andrews GP
    Mol Pharm; 2015 Apr; 12(4):1180-92. PubMed ID: 25692314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Barrier coated drug layered particles for enhanced performance of amorphous solid dispersion dosage form.
    Puri V; Dantuluri AK; Bansal AK
    J Pharm Sci; 2012 Jan; 101(1):342-53. PubMed ID: 21935949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement.
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    Pharm Dev Technol; 2011 Jun; 16(3):187-200. PubMed ID: 20429826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amorphous solid dispersions: An update for preparation, characterization, mechanism on bioavailability, stability, regulatory considerations and marketed products.
    Pandi P; Bulusu R; Kommineni N; Khan W; Singh M
    Int J Pharm; 2020 Aug; 586():119560. PubMed ID: 32565285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase separation in coamorphous systems: in silico prediction and the experimental challenge of detection.
    Pajula K; Wittoek L; Lehto VP; Ketolainen J; Korhonen O
    Mol Pharm; 2014 Jul; 11(7):2271-9. PubMed ID: 24824610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of polymer type on bioperformance and physical stability of hot melt extruded formulations of a poorly water soluble drug.
    Mitra A; Li L; Marsac P; Marks B; Liu Z; Brown C
    Int J Pharm; 2016 May; 505(1-2):107-14. PubMed ID: 27012984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Solid state drug-polymer miscibility studies using the model drug ABT-102.
    Jog R; Gokhale R; Burgess DJ
    Int J Pharm; 2016 Jul; 509(1-2):285-295. PubMed ID: 27265312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physical Stability of Amorphous Solid Dispersions: a Physicochemical Perspective with Thermodynamic, Kinetic and Environmental Aspects.
    Lin X; Hu Y; Liu L; Su L; Li N; Yu J; Tang B; Yang Z
    Pharm Res; 2018 Apr; 35(6):125. PubMed ID: 29687226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Considerations for the selection of co-formers in the preparation of co-amorphous formulations.
    Yarlagadda DL; Sai Krishna Anand V; Nair AR; Navya Sree KS; Dengale SJ; Bhat K
    Int J Pharm; 2021 Jun; 602():120649. PubMed ID: 33915186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug.
    Lakshman JP; Cao Y; Kowalski J; Serajuddin AT
    Mol Pharm; 2008; 5(6):994-1002. PubMed ID: 19434852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amorphous solid dispersions: a robust platform to address bioavailability challenges.
    Newman A; Nagapudi K; Wenslow R
    Ther Deliv; 2015 Feb; 6(2):247-61. PubMed ID: 25690090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel methods for the assessment of miscibility of amorphous drug-polymer dispersions.
    Ivanisevic I; Bates S; Chen P
    J Pharm Sci; 2009 Sep; 98(9):3373-86. PubMed ID: 19283767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The formation and physical stability of two-phase solid dispersion systems of indomethacin in supercooled molten mixtures with different matrix formers.
    Semjonov K; Kogermann K; Laidmäe I; Antikainen O; Strachan CJ; Ehlers H; Yliruusi J; Heinämäki J
    Eur J Pharm Sci; 2017 Jan; 97():237-246. PubMed ID: 27890595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amino acids as co-amorphous stabilizers for poorly water-soluble drugs--Part 2: molecular interactions.
    Löbmann K; Laitinen R; Strachan C; Rades T; Grohganz H
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):882-8. PubMed ID: 23567485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Qualitative and quantitative methods to determine miscibility in amorphous drug-polymer systems.
    Meng F; Dave V; Chauhan H
    Eur J Pharm Sci; 2015 Sep; 77():106-11. PubMed ID: 26006307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A rational approach towards development of amorphous solid dispersions: Experimental and computational techniques.
    Chakravarty P; Lubach JW; Hau J; Nagapudi K
    Int J Pharm; 2017 Mar; 519(1-2):44-57. PubMed ID: 28063904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. smartPearls - Novel physically stable amorphous delivery system for poorly soluble dermal actives.
    Müller RH; Hespeler D; Jin N; Pyo SM
    Int J Pharm; 2019 Jan; 555():314-321. PubMed ID: 30439490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.